Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 44
Filtrar
1.
J Intensive Care Med ; 37(10): 1336-1343, 2022 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-35285742

RESUMEN

BACKGROUND: Pulmonary embolism (PE) with cor pulmonale causes considerable mortality and morbidity. Randomized trials have failed to show a mortality difference between treatment modalities including anticoagulation (AC), Catheter directed thrombolysis (CDT) and systemic tPA (tissue plasminogen activator). METHODS: This is a cross-sectional retrospective case-control study utilizing the 2017 National Inpatient Sample (NIS). Patients admitted with acute PE with cor pulmonale were divided into groups based on whether they received anticoagulation, CDT or systemic tPA based on appropriate ICD-10 PCS codes. The AC group and CDT group were compared using univariate and multivariate analyses after adjusting for age, gender, race, comorbidities, insurance status and Charlson comorbidity index (CCI). Secondary outcomes included factors influencing length of stay (LOS) and total charges incurred. Similar analyses were done to compare the CDT group with the tPA group. RESULTS: In 2017, 13240 patients were admitted with acute PE and cor pulmonale, of whom 18% underwent CDT, 10% underwent systemic tPA and 72% underwent AC alone. Patients who received CDT over AC alone were significantly younger (61.5 vs. 65.5, p = 0.00). Mortality rate overall was 4.8% with tPA group, CDT group and AC alone group having a 11.2%, 3.0% and 4.4% mortality rate respectively. On multivariate analyses, there was no significant mortality difference between the CDT and AC groups (aOR 0.61, 0.34-1.1 95%CI, p = 0.103). Patients with liver disease had significantly higher mortality while obese patients had a significantly lower mortality after adjusting for treatment strategy and confounders. Length of stay (LOS) was not significantly different between the groups however, compared to AC alone, patients who underwent CDT or tPA incurred significantly higher total hospital charges. CONCLUSIONS: CDT offers an attractive alternative to tPA therapy; however, our study does not show an in-hospital mortality benefit. More studies are required to guide patient selection prior to establishing treatment protocols.


Asunto(s)
Embolia Pulmonar , Enfermedad Cardiopulmonar , Enfermedad Aguda , Anticoagulantes , Estudios de Casos y Controles , Catéteres , Estudios Transversales , Fibrinolíticos/uso terapéutico , Humanos , Embolia Pulmonar/complicaciones , Embolia Pulmonar/tratamiento farmacológico , Enfermedad Cardiopulmonar/inducido químicamente , Enfermedad Cardiopulmonar/tratamiento farmacológico , Estudios Retrospectivos , Terapia Trombolítica/métodos , Factores de Tiempo , Activador de Tejido Plasminógeno/uso terapéutico , Resultado del Tratamiento
2.
Clin Exp Pharmacol Physiol ; 47(3): 478-484, 2020 03.
Artículo en Inglés | MEDLINE | ID: mdl-31730233

RESUMEN

The right ventricle (RV) enlargement and pulmonary fibrosis are involved in cor pulmonale. The role of miR-200b in cor pulmonale is less well understood. This study was designed to evaluate the regulatory roles of miR-200b in cor pulmonale. Cor pulmonary mouse model was built via monocrotaline injection of monocrotaline (MCT). The expression of miR-200b in the lungs, RV and left ventricle (LV) are using real-time polymerase chain reaction. The transthoracic echocardiography was employed to determine the effects of miR-200b mimics and Gö6976 injection on MCT mice. The protein levels of protein kinase C α (PKCα), collagen, and fibronectin in the lung, RV, and LV in the mice with and without miR-200b mimics and Gö6976 injection were evaluated using western blot. The expression of miR-200b decreased in MCT mice, while there was no difference in LV. Both the miR-200b mimics and Gö6976 injection reversed the muscularization in the pulmonary artery, reversed RV hypertrophy, reduced RV systolic pressure, wall thickness and pulmonary fibrosis. The injection of miR-200b can reduce the PKCα expression in the lung, RV, and LV. This study confirmed the down-regulation of miR-200b in cor pulmonale. The reverse effects of miR-200b in the present study may provide a potential tool for cor pulmonary treatment.


Asunto(s)
Modelos Animales de Enfermedad , Hipertensión Pulmonar/metabolismo , MicroARNs/metabolismo , Proteína Quinasa C-alfa/biosíntesis , Enfermedad Cardiopulmonar/metabolismo , Transducción de Señal/fisiología , Animales , Hipertensión Pulmonar/inducido químicamente , Hipertensión Pulmonar/prevención & control , Masculino , Ratones , Ratones Endogámicos C57BL , Monocrotalina/toxicidad , Proteína Quinasa C-alfa/antagonistas & inhibidores , Enfermedad Cardiopulmonar/inducido químicamente , Enfermedad Cardiopulmonar/prevención & control , Transducción de Señal/efectos de los fármacos
3.
Environ Health ; 18(1): 64, 2019 07 15.
Artículo en Inglés | MEDLINE | ID: mdl-31307485

RESUMEN

BACKGROUND: Pulmonary heart disease (PHD) has become a global burden, especially in low- and middle-income countries. However, very few studies have assessed the influence of air pollution on PHD. This is the first study to explore the association between gaseous pollutants and PHD-related mortality in the central Sichuan Basin of southwestern China. METHODS: Data on PHD-related mortality among elderly people (aged 60 and older) from 2013 to 2017 were collected from the Population Death Information Registration and Management System (PDIRMS). Data on air pollutants were collected from all 24 Municipal Environmental Monitoring Sites in Chengdu, and data on daily temperature, relative humidity, and atmospheric pressure were collected from the Chengdu Municipal Meteorological Bureau. An epidemiological design of time-stratified case-crossover was conducted to assess the association between short-term exposure to ambient gaseous pollutants and PHD-related mortality among elderly people. RESULTS: About 54,920 PHD-related deaths among people aged 60 and older were reported. After controlling for daily temperature, relative humidity, and atmospheric pressure, an IQR concentration increase in levels of sulfur dioxide (SO2) (13 µg/m3), nitrogen dioxide (NO2) (17 µg/m3), and ozone (O3) (74 µg/m3) was associated with 7.8, 6.2, and 5.5% increases in PHD-related mortality in people aged 60 and older, respectively. People over age 70 might have even higher susceptibility to PHD-related mortality associated with SO2, NO2, and O3. Females and individuals with alternative marital statuses (widowed, divorced, or never married) had twice and more than twice the PHD-related mortality risk associated with SO2 and NO2 than males and married individuals, respectively. CONCLUSIONS: Increased concentrations of ambient SO2, NO2, and O3 were significantly and positively associated with PHD-related mortality in Chengdu, China. Sociodemographic factors - including gender, age, and marital status - may modify the acute health effects of gaseous pollutants.


Asunto(s)
Contaminantes Atmosféricos/efectos adversos , Contaminación del Aire/efectos adversos , Exposición a Riesgos Ambientales , Gases/efectos adversos , Enfermedad Cardiopulmonar/mortalidad , Anciano , Anciano de 80 o más Años , China/epidemiología , Estudios Cruzados , Femenino , Humanos , Masculino , Persona de Mediana Edad , Enfermedad Cardiopulmonar/inducido químicamente , Factores de Tiempo
4.
PLoS One ; 13(7): e0198681, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30044773

RESUMEN

E-cigarettes are promoted as healthier alternatives to conventional cigarettes. Many cigarette smokers use both products. It is unknown whether the additional use of e-cigarettes among cigarette smokers (dual users) is associated with reduced exposure to tobacco-related health risks. Cross-sectional analysis was performed using baseline data from the Health eHeart Study, among English-speaking adults, mostly from the United States. Cigarette use (# cigarettes/day) and/or e-cigarette use (# days, # cartridges, and # puffs) were compared between cigarette only users vs. dual users. Additionally, we examined cardiopulmonary symptoms/ conditions across product use: no product (neither), e-cigarettes only, cigarettes only, and dual use. Among 39,747 participants, 573 (1.4%) reported e-cigarette only use, 1,693 (4.3%) reported cigarette only use, and 514 (1.3%) dual use. Dual users, compared to cigarette only users, reported a greater median (IQR) number of cigarettes per day, 10.0 (4.0-20.0) vs. 9.0 (3.0-15.0) (p < .0001), a lower (worse) median (IQR) SF-12 general health score, 3.3 (2.8-3.8) vs. 3.5 (2.8-3.9) (p = .0014), and a higher (worse) median (IQR) breathing difficulty score in the past month, 2.0 (1.0-2.0) vs. 1.0 (1.0-2.0) (p = .001). Of the 19 cardiopulmonary symptoms/ conditions, having a history of arrhythmia was significantly different between cigarette only users (14.2%) and dual users (17.8%) (p = .02). In this sample, dual use was not associated with reduced exposure to either (i) cigarettes, compared to cigarette only users or (ii) e-cigarettes, compared to e-cigarette only users. E-cigarette only use, compared to no product use, was associated with lower general health scores, higher breathing difficulty scores (typically and past month), and greater proportions of those who responded 'yes' to having chest pain, palpitations, coronary heart disease, arrhythmia, COPD, and asthma. These data suggest the added use of e-cigarettes alone may have contributed to cardiopulmonary health risks particularly respiratory health risks.


Asunto(s)
Asma/epidemiología , Enfermedad Cardiopulmonar/epidemiología , Productos de Tabaco/efectos adversos , Vapeo/efectos adversos , Adulto , Asma/inducido químicamente , Asma/fisiopatología , Sistemas Electrónicos de Liberación de Nicotina , Femenino , Corazón/efectos de los fármacos , Corazón/fisiopatología , Humanos , Masculino , Persona de Mediana Edad , Enfermedad Cardiopulmonar/inducido químicamente , Enfermedad Cardiopulmonar/fisiopatología , Factores de Riesgo , Nicotiana/efectos adversos
5.
J Cardiovasc Pharmacol ; 66(3): 246-53, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-25923321

RESUMEN

Pulmonary arterial hypertension is characterized by progressive increases in resistance and pressure in the pulmonary artery and Cor pulmonale. The effect of exercise on hydrogen peroxide-dependent signaling in the right ventricle (RV) of Cor pulmonale rats was analyzed. Rats were divided into sedentary control (SC), sedentary monocrotaline (SM), trained control (TC), and trained monocrotaline (TM) groups. Rats underwent exercise training (60% of VO2 max) for 5 weeks, with 3 weeks after monocrotaline injection (60 mg/kg intraperitoneally). Pulmonary resistance was enhanced in SM (2.0-fold) compared with SC. Pulmonary artery pressure was increased in SM (2.7-fold) and TM (2.6-fold) compared with their respective controls (SC and TC). RV hypertrophy indexes increased in SM compared with SC. Hydrogen peroxide was higher in SM (1.7-fold) than SC and was reduced by 47% in TM compared with SM. p-Akt was increased in TM (2.98-fold) compared with SM. The Bax/Bcl-2 ratio and caspase 3 were also increased (2.9-fold and 3.9-fold, respectively) in SM compared with SC. Caspase 3 was decreased in TM compared with SM (P < 0.05). Therefore, exercise training promoted a beneficial response by decreasing hydrogen peroxide concentrations, and consequently, apoptotic signaling in RV.


Asunto(s)
Proteínas Reguladoras de la Apoptosis/metabolismo , Apoptosis , Hipertrofia Ventricular Derecha/fisiopatología , Condicionamiento Físico Animal/fisiología , Arteria Pulmonar/fisiopatología , Enfermedad Cardiopulmonar/fisiopatología , Animales , Apoptosis/fisiología , Modelos Animales de Enfermedad , Ecocardiografía , Hemodinámica/efectos de los fármacos , Hemodinámica/fisiología , Peróxido de Hidrógeno/metabolismo , Hipertrofia Ventricular Derecha/metabolismo , Hipertrofia Ventricular Derecha/patología , Masculino , Monocrotalina/farmacología , Enfermedad Cardiopulmonar/inducido químicamente , Enfermedad Cardiopulmonar/metabolismo , Enfermedad Cardiopulmonar/patología , Ratas Wistar , Resistencia Vascular/fisiología , Función Ventricular Derecha/efectos de los fármacos , Función Ventricular Derecha/fisiología , Remodelación Ventricular/efectos de los fármacos , Remodelación Ventricular/fisiología
6.
Dtsch Med Wochenschr ; 138(22): 1159-62, 2013 May.
Artículo en Alemán | MEDLINE | ID: mdl-23700302

RESUMEN

HISTORY: A 32-year-old woman was admitted to the emergency department because of acute dyspnea and syncope. A few minutes before the onset of symptoms, she had self-administered an intravenous injection of one gram of heroin combined with grinded flunitrazepam tablets. INVESTIGATIONS: Signs of acute cor pulmonale were detected on transthoracic echocardiography despite lack of pulmonary embolism in computed tomography. It was assumed that microembolisms were the cause of acute pulmonary hypertension after intravenous injection of heroin and flunitrazepam. TREATMENT AND COURSE: Because of lack of thrombus in CT scan therapeutic anticoagulation with unfractionated heparin and oxygen insufflation was initiated resulting in rapid improvement of oxygen saturation and blood pressure. On the following day pulmonary pressure in transthoracic echocardiography was already decreased significantly. Without signs of deep venous thrombosis in duplex scan and only a marginal sub segmental perfusion deficit in ventilation-perfusion-scintigraphy therapeutic anticoagulation was recommended for three months. CONCLUSION: The most likely cause of micro embolisms in this case are particles of talc, which are often used to cut heroin, or the microcrystalline cellulose used in tablets. There have been reports of tissue necrosis due to arterial embolism/vasospasm by crystalloid or oily substances (embolia cutis medicamentosa) in the extremities after intraarterial injection of grinded flunitrazepam tablets. Therefore it seems plausible that intravenous application may cause a serve but transient deficit of perfusion in pulmonary circulation.


Asunto(s)
Flunitrazepam/toxicidad , Heroína/envenenamiento , Enfermedad Cardiopulmonar/inducido químicamente , Abuso de Sustancias por Vía Intravenosa/complicaciones , Abuso de Sustancias por Vía Intravenosa/diagnóstico , Disfunción Ventricular Derecha/inducido químicamente , Adulto , Diagnóstico Diferencial , Femenino , Flunitrazepam/administración & dosificación , Heroína/administración & dosificación , Humanos , Enfermedad Cardiopulmonar/diagnóstico , Enfermedad Cardiopulmonar/terapia , Disfunción Ventricular Derecha/diagnóstico , Disfunción Ventricular Derecha/terapia
7.
J Physiol Sci ; 63(1): 55-62, 2013 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-23015108

RESUMEN

Intravenous hyperosmotic NaCl infusion is an effective treatment for circulatory shock. However, a fast infusion rate (2 mL/kg at the rate of 1 mL/s) induces transient hypotension. This response has been reported to be due to decreased total peripheral resistance and/or decreased cardiac performance. Although the hypotension is transient and recovers within 2 min without detrimental consequences, it is important to understand the associated hemodynamics and mechanisms. We found that the hypotensive effect was larger with intravenous NaCl infusion than with intra-aortic infusion, indicating that change in cardiac performance played a more significant role than change in peripheral resistance. NaCl infusion induced an increase in pulmonary vascular resistance and central venous pressure and a decrease in right ventricular dP/dt max, suggesting acute cor pulmonale. Diastolic ventricular crosstalk-induced left ventricular failure was also observed. Hyperosmotic NaCl-induced hypotension was therefore mainly due to a combination of acute cor pulmonale and left ventricular failure.


Asunto(s)
Enfermedad Cardiopulmonar/inducido químicamente , Solución Salina Hipertónica/toxicidad , Cloruro de Sodio/toxicidad , Animales , Presión Sanguínea/efectos de los fármacos , Presión Sanguínea/fisiología , Presión Venosa Central/efectos de los fármacos , Presión Venosa Central/fisiología , Corazón/efectos de los fármacos , Corazón/fisiopatología , Insuficiencia Cardíaca/inducido químicamente , Insuficiencia Cardíaca/fisiopatología , Hemodinámica/efectos de los fármacos , Hemodinámica/fisiología , Infusiones Intravenosas , Masculino , Enfermedad Cardiopulmonar/fisiopatología , Ratas , Ratas Sprague-Dawley , Resistencia Vascular/efectos de los fármacos , Resistencia Vascular/fisiología , Disfunción Ventricular Izquierda/inducido químicamente , Disfunción Ventricular Izquierda/fisiopatología
8.
Artículo en Chino | MEDLINE | ID: mdl-22860411

RESUMEN

OBJECTIVE: To explore the mechanism of pulmonary hypertension and Cor Pulmonale rat models induced by monocrotaline (MCT). METHODS: Twenty Wistar male rats were randomly divided into normal control group and model group (n= 10), which received a single intraperitoneal injection of MCT solution (50 mg/kg , the first day) or dissolvant, respectively. On day 28 after MCT administration, the hemodynamic parameters were assessed; levels of tumour necrosis factor-alpha (TNF-alpha), nitric oxide (NO), endothelin-1 (ET-1), B-type natriuretic peptide(BNP) in pulmonary tissue or blood were measured using radio immunoassay or nitrate reductase method. RESULTS: 28 days after MCT injection, compared with control group, right ventricle systolic pressure (RVSP) increased and heart rate(HR), mean arterial pressure (MAP) decreased; Levels of TNF-alpha, NO, ET-1 in pulmonary tissue or blood increased significantly in MCT group. CONCLUSION: The potential mechanism of MCI- induced pulmonary hypertension and Cor Pulmonale rat models associates with increasing TNF-alpha, NO, ET-1 levels in vivo, which results from inflammatory injury of lung tissue and blood vessels induced by MCT.


Asunto(s)
Hipertensión Pulmonar/fisiopatología , Monocrotalina/efectos adversos , Enfermedad Cardiopulmonar/fisiopatología , Animales , Modelos Animales de Enfermedad , Endotelina-1/metabolismo , Hipertensión Pulmonar/inducido químicamente , Hipertensión Pulmonar/metabolismo , Pulmón/metabolismo , Masculino , Óxido Nítrico/metabolismo , Enfermedad Cardiopulmonar/inducido químicamente , Enfermedad Cardiopulmonar/metabolismo , Ratas , Ratas Wistar , Factor de Necrosis Tumoral alfa/metabolismo
9.
Free Radic Biol Med ; 53(2): 216-29, 2012 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-22583703

RESUMEN

The development of pulmonary hypertension is a common accompaniment of congenital heart disease (CHD) with increased pulmonary blood flow. Our recent evidence suggests that asymmetric dimethylarginine (ADMA)-induced mitochondrial dysfunction causes endothelial nitric oxide synthase (eNOS) uncoupling secondary to a proteasome-dependent degradation of GTP cyclohydrolase I (GCH1) that results in a decrease in the NOS cofactor tetrahydrobiopterin (BH(4)). Decreases in NO signaling are thought to be an early hallmark of endothelial dysfunction. As l-carnitine plays an important role in maintaining mitochondrial function, in this study we examined the protective mechanisms and the therapeutic potential of l-carnitine on NO signaling in pulmonary arterial endothelial cells and in a lamb model of CHD and increased pulmonary blood flow (Shunt). Acetyl-l-carnitine attenuated the ADMA-mediated proteasomal degradation of GCH1. This preservation was associated with a decrease in the association of GCH1 with Hsp70 and the C-terminus of Hsp70-interacting protein (CHIP) and a decrease in its ubiquitination. This in turn prevented the decrease in BH(4) levels induced by ADMA and preserved NO signaling. Treatment of Shunt lambs with l-carnitine also reduced GCH1/CHIP interactions, attenuated the ubiquitination and degradation of GCH1, and increased BH(4) levels compared to vehicle-treated Shunt lambs. The increases in BH(4) were associated with decreased NOS uncoupling and enhanced NO generation. Thus, we conclude that L-carnitine may have a therapeutic potential in the treatment of pulmonary hypertension in children with CHD with increased pulmonary blood flow.


Asunto(s)
Acetilcarnitina/uso terapéutico , Células Endoteliales/efectos de los fármacos , GTP Ciclohidrolasa/metabolismo , Hipertensión Pulmonar/tratamiento farmacológico , Complejo de la Endopetidasa Proteasomal/metabolismo , Enfermedad Cardiopulmonar/tratamiento farmacológico , Proteínas Adaptadoras Transductoras de Señales/metabolismo , Animales , Animales Recién Nacidos , Arginina/análogos & derivados , Arginina/farmacología , Biopterinas/análogos & derivados , Biopterinas/biosíntesis , Modelos Animales de Enfermedad , Células Endoteliales/patología , Femenino , Proteínas HSP70 de Choque Térmico/metabolismo , Hipertensión Pulmonar/inducido químicamente , Hipertensión Pulmonar/cirugía , Mitocondrias/efectos de los fármacos , Mitocondrias/metabolismo , Óxido Nítrico/biosíntesis , Óxido Nítrico Sintasa/metabolismo , Embarazo , Inhibidores de Proteasoma/farmacología , Arteria Pulmonar/efectos de los fármacos , Arteria Pulmonar/patología , Enfermedad Cardiopulmonar/inducido químicamente , Enfermedad Cardiopulmonar/cirugía , Ovinos , Transducción de Señal , Ubiquitina-Proteína Ligasas/metabolismo , Ubiquitinación
10.
South Med J ; 103(2): 116-20, 2010 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-20065909

RESUMEN

BACKGROUND: The occurrence of deteriorating renal function test results along with the attempts at diuresis of anasarca has been described but not named, and no solution other than the standard treatment of related medical conditions such as congestive heart failure (CHF) and reducing or stopping diuretics has been offered. Phosphodiesterase type 5 inhibitors (PD5I) are known to reduce pulmonary hypertension (PH). The PD5Is sildenafil and, just recently, tadalafil, have FDA indications in primary pulmonary hypertension (PPH). METHODS: In this observational study of CorPRADA patients treated with PD5I, 12 out of 19 cases met criteria for inclusion in statistical analysis. Medication reductions/discontinuations generally were made. Pre- and post-treatment data were analyzed using matched pairs. RESULTS: There were significant improvements in edema, glomerular filtration rate (GFR), weight, and loop diuretic dosage required, while strong trends were seen in urine output per day and urine output per unit loop diuretic per day. CONCLUSION: The identification of CorPRADA and the use of standard treatments for PH plus PD5I medication show promise in achieving successful diuresis of anasarca while stabilizing or improving renal function simultaneously.


Asunto(s)
Azotemia/tratamiento farmacológico , Carbolinas/uso terapéutico , Diuréticos/uso terapéutico , Edema/tratamiento farmacológico , Inhibidores de Fosfodiesterasa/uso terapéutico , Piperazinas/uso terapéutico , Enfermedad Cardiopulmonar/tratamiento farmacológico , Sulfonas/uso terapéutico , Presión Sanguínea/efectos de los fármacos , Carbolinas/administración & dosificación , Diuresis/efectos de los fármacos , Diuréticos/efectos adversos , Tasa de Filtración Glomerular/efectos de los fármacos , Humanos , Hipertensión Pulmonar/tratamiento farmacológico , Inhibidores de Fosfodiesterasa/administración & dosificación , Piperazinas/administración & dosificación , Enfermedad Cardiopulmonar/inducido químicamente , Purinas/administración & dosificación , Purinas/uso terapéutico , Citrato de Sildenafil , Sulfonas/administración & dosificación , Tadalafilo
11.
J Appl Toxicol ; 27(6): 538-50, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17351914

RESUMEN

A study was conducted of acute intoxication of infant and adult Wistar rats with fluoroacetamide (FAA), an inhibitor of oxidative metabolism. FAA was administered orally to adult rats at 1/2 LD(50) and subcutaneously to infant rats at LD(100) or 1/10 LD(50). Electrocardiogram (ECG), respiration and motor activity were registered for 7 days. Clinical analysis of ECG and the heart rate variability (HRV) was carried out to assess the state of the vegetative nervous system. In adult rats, FAA caused marked disturbances in the activity of cardiovascular and respiratory systems, including the development of a potentially lethal acute cor pulmonale. Conversely, there were no significant changes of cardiac function and respiration in infant rats; they died because of extreme emaciation accompanied by retardation of development. In adult rats, bursts of associated cardiac and respiratory tachyarrhythmia, as well as regular high amplitude spasmodic sighs having a deca-second rhythm were observed. In both infant and adult rats, FAA caused short-term enhancement of humoral (metabolic) and sympathetic activities, followed by a gradual and stable predominance of parasympathetic influence on HRV. Under conditions of FAA inhibition of the tricarboxylic acid cycle, the observed physiological reactions may be explained by activation of alternative metabolic pathways. This is also supported by a lack of ontogenetically caused inhibition of spontaneous motor activity in infant rats poisoned with FAA, which highlights the significance of the alternative metabolic pathways for implementation of deca-second and minute rhythms and a lack of a rigid dependence of these rhythms upon activity of neuronal networks.


Asunto(s)
Envejecimiento , Inhibidores Enzimáticos/toxicidad , Fluoroacetatos/toxicidad , Frecuencia Cardíaca/efectos de los fármacos , Corazón/efectos de los fármacos , Actividad Motora/efectos de los fármacos , Respiración/efectos de los fármacos , Enfermedad Aguda , Administración Oral , Factores de Edad , Animales , Animales Recién Nacidos , Arritmias Cardíacas/inducido químicamente , Arritmias Cardíacas/fisiopatología , Relación Dosis-Respuesta a Droga , Electrocardiografía , Metabolismo Energético/efectos de los fármacos , Inhibidores Enzimáticos/administración & dosificación , Fluoroacetatos/administración & dosificación , Corazón/inervación , Inyecciones Subcutáneas , Sistema Nervioso Parasimpático/efectos de los fármacos , Sistema Nervioso Parasimpático/fisiopatología , Enfermedad Cardiopulmonar/inducido químicamente , Enfermedad Cardiopulmonar/fisiopatología , Ratas , Ratas Wistar , Sistema Nervioso Simpático/efectos de los fármacos , Sistema Nervioso Simpático/fisiopatología , Factores de Tiempo , Pruebas de Toxicidad Aguda
15.
Toxicol Appl Pharmacol ; 118(1): 87-97, 1993 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-8430429

RESUMEN

Monocrotaline (MCT) produces pulmonary hypertension and right ventricular hypertrophy in rats. It is generally believed that MCT must undergo hepatic metabolism to reactive metabolites that are subsequently transported to the lungs to induce a pneumotoxic response. Several studies suggest that dehydromonocrotaline (MCTP) is the reactive intermediate that initiates pulmonary toxicity. We recently identified two other MCT metabolites, the glutathione and N-acetylcysteine conjugates of 6,7-dihydro-7-hydroxy-1-hydromethyl-5H-pyrrolizine (DHP). To determine the potential pulmonary toxicity of the glutathione conjugate (DHP-GSH) and the unacetylated cysteine conjugate precursor (DHP-Cys) of the N-acetylated excretion product, we conducted parallel in vivo toxicity studies with DHP-GSH, DHP-Cys, MCT, and MCTP. Relative pneumotoxicity was evaluated by measurements of right ventricular pressure (RVP), ventricular weight ratio (RV/LV+S), subjective histopathology, and measurements of components of the arteriolar wall. Animals given a single injection of MCT (60 mg/kg) developed pulmonary hypertension at the end of 3 weeks, as indicated by significant elevation in RVP when compared to the controls (22.1 +/- 2.4 mm Hg vs 13.2 +/- 0.8 mm Hg). A parallel and significant increase in RV/LV+S was also evident: 0.37 +/- 0.021 (MCT) vs 0.299 +/- 0.011 (control). Histopathology showed marked alterations in both pulmonary vasculature and parenchyma in MCT- and MCTP-treated animals. MCTP (1 mg/kg) caused a significantly elevated RVP (MCTP vs control: 28.1 +/- 3.4 mm Hg vs 16.8 +/- 0.97 mm Hg) and an increased RV/LV+S (MCTP vs control: 0.445 +/- 0.051 vs 0.284 +/- 0.026). Both MCT- and MCTP-treated rats had increased arteriolar medial thickness and decreased lumen diameter, but MCTP-treated rats had a milder vascular inflammatory response and less parenchymal lesions. Neither DHP-GSH (24 or 12 mg/kg) nor DHP-Cys (12 mg/kg) caused detectable changes in pulmonary circulation and no structural alteration in the lung was observed in these treatment groups. Although they are all pyrrolic metabolites of MCT, these studies demonstrate that only MCTP but not the glutathione or cysteine conjugates, is pneumotoxic at the doses tested.


Asunto(s)
Cisteína/toxicidad , Glutatión/toxicidad , Monocrotalina/análogos & derivados , Monocrotalina/toxicidad , Enfermedad Cardiopulmonar/inducido químicamente , Animales , Peso Corporal/efectos de los fármacos , Pulmón/efectos de los fármacos , Pulmón/patología , Masculino , Monocrotalina/metabolismo , Ratas , Ratas Sprague-Dawley
18.
Lab Invest ; 52(3): 298-303, 1985 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-3156262

RESUMEN

Methylprednisolone (MP) has been shown to reduce acute lung edema caused by monocrotaline (MCT), but its effect on MCT-induced pulmonary hypertension has not previously been reported. We have examined the effects of MP on MCT-induced pulmonary vascular remodeling and right ventricular hypertrophy using five groups of rats. Group 1 received nothing and acted as control; group 2 and all other groups received MCT as a single injection; group 3 was given low-dose MP by daily injection starting 24 hours after the MCT; group 4 was given MP as two high-dose pulses 2 hours before and 22 hours after MCT; group 5, acting as control for injection, received an injection of water 2 hours before MCT and daily for 21 days. All animals were killed 21 days after the MCT was given; ventricular weights were determined, and the lung vasculature was analyzed morphometrically. In each of the last three groups, the "treatment" reduced the increase in arterial medial thickness, "extension" of muscle to intraacinar pulmonary arteries, number of vessels with "occluded" lumen, and right ventricular hypertrophy--the features caused by MCT alone. For all four features, the effectiveness of a given regimen was similar. Daily MP prevented three-quarters of the ventricular ratio change, whereas pulse MP and daily water prevented one-half. The protection given by daily water injection may relate to autologous hormone production (steroid or other) from stress of injections. Daily MP, given after the acute MCT injury has occurred, protects more effectively than a high-dose pulse given at the time of injury. We suggest that the acute phase of MCT injury causes secondary changes that, although triggered by the acute lesion, become self-sustaining and are more significant for vascular structural remodeling.


Asunto(s)
Cardiomegalia/inducido químicamente , Metilprednisolona/uso terapéutico , Enfermedad Cardiopulmonar/inducido químicamente , Alcaloides de Pirrolicidina , Animales , Peso Corporal , Cardiomegalia/tratamiento farmacológico , Ventrículos Cardíacos , Hipertensión Pulmonar/patología , Masculino , Monocrotalina , Enfermedad Cardiopulmonar/tratamiento farmacológico , Ratas , Ratas Endogámicas
20.
Thorax ; 37(2): 88-96, 1982 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-6281933

RESUMEN

We have investigated the role of angiotensin converting enzyme (ACE) in the development of pulmonary hypertension, right ventricular hypertrophy, and pulmonary vascular disease in rats given a single subcutaneous injection of the pyrrolizidine alkaloid monocrotaline. Thirty-six young female Wistar rats were divided into a test group of 27 animals and a control group of nine animals. Each test rat was given a single subcutaneous injection of monocrotaline (60 mg/kg body weight). On the first, third, fifth, seventh, tenth, twelfth, fourteenth, seventeenth, and twenty-second days after the injection of monocrotaline the mean right ventricular systolic blood pressure was measured in one control and three test rats. The animals were then killed and we measured the specific activity of ACE in serum and lung homogenate. We also evaluated muscularisation of pulmonary arterioles, medial hypertrophy of muscular pulmonary arteries, and right ventricular hypertrophy. The sequence of changes was as follows: muscularisation of pulmonary arterioles and medial hypertrophy of muscular pulmonary arteries were apparent seven days after administration of monocrotaline; pulmonary hypertension and reduced lung ACE activity occurred after 10 days; right ventricular hypertrophy was detected after 12 days. Serum ACE activity was unchanged. It is concluded that the reduction in lung ACE activity is a result rather than a cause of the pulmonary hypertension. This reduction in lung ACE activity may be a protective mechanism designed to limit the elevation of the pulmonary arterial pressure.


Asunto(s)
Hipertensión Pulmonar/inducido químicamente , Peptidil-Dipeptidasa A/sangre , Alcaloides de Pirrolicidina/efectos adversos , Animales , Arteriolas/patología , Presión Sanguínea/efectos de los fármacos , Cardiomegalia/inducido químicamente , Femenino , Hipertensión Pulmonar/enzimología , Pulmón/análisis , Pulmón/irrigación sanguínea , Pulmón/fisiopatología , Monocrotalina , Músculo Liso Vascular/patología , Arteria Pulmonar/patología , Enfermedad Cardiopulmonar/inducido químicamente , Ratas , Ratas Endogámicas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...